Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioWa has licensed Potelligent Technology to Agensys, an affiliate of Tokyo based Astellas Pharma, for the purpose of identifying antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC).
Subscribe to our email newsletter
Potelligent Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout Chinese Hamster Ovary (CHO) cell line as a production cell.
As per the terms of the license agreement, BioWa grants Agensys non-exclusive rights to conduct research activities using Potelligent Technology for an undisclosed number of targets.
In return, BioWa will receive annual research license fees.
BioWa president and CEO Masamichi Koike said that they are extremely pleased about the agreement with Agensys, a monoclonal antibody organisation with a focus on therapies against solid tumors.
"Agensys R&D organisation and breath of targets in solid tumors will greatly extend the benefits of the Potelligent Technology," Koike said.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin, Japan’s pharmaceutical and biotech company, and is the exclusive worldwide licensor for the AccretaMab platform. The AccretaMab platform consists of Potelligent and Complegent Technologies, creating antibody molecules with ADCC and CDC activities.